ChemT Biotechnology Raises US$5 Million in 18 months to bring AI to Biomanufacturing

ChemT Biotechnology has successfully closed a $4 million seed funding round, led by Wavemaker Ventures, with participation from SEEDS and other notable investors. The funding, which is part of a total capital raise of $5 million that includes $1 million in angel investment, was announced on June 22, 2026. This financing will be instrumental in advancing ChemT's AI-driven biomanufacturing capabilities, aimed at streamlining the production of advanced medicines.

ChemT Biotechnology, operating across Singapore and the United States, is focused on integrating artificial intelligence into the biomanufacturing process. The company’s flagship technology, CelMo™, is an AI-driven Virtual Cell platform that leverages extensive biological data to improve the efficiency and scalability of biologics production. Traditional biomanufacturing methods often encounter significant challenges, including lengthy development timelines, unpredictable yields, and high costs. ChemT’s innovative approach seeks to address these issues by enabling a more precise manipulation of cellular processes, which is critical for producing biologics at scale.

The strategic rationale behind this funding round is to enhance ChemT's experimental infrastructure and to further develop its AI-designed molecular products towards Good Manufacturing Practice (GMP) standards. The investment will also support the scaling of commercial partnerships, which have already seen ChemT collaborating with over 40 pharmaceutical and biotech companies globally. By expanding its capabilities beyond Chinese Hamster Ovary (CHO) cells and T-cells into other cellular systems, ChemT aims to provide broader intelligent control across various biomanufacturing workflows.

The biotechnology sector is currently witnessing a surge in interest, particularly in AI-driven solutions that promise to revolutionize traditional manufacturing processes. ChemT's focus on integrating intelligence into biomanufacturing aligns with broader industry trends that emphasize efficiency and cost-effectiveness. As companies increasingly seek to overcome the structural bottlenecks that have historically plagued biomanufacturing, ChemT's innovative solutions position it favorably within this dynamic landscape.

Looking ahead, the successful completion of this funding round not only validates ChemT's technology and business model but also highlights the growing investor confidence in AI applications within the life sciences. As the demand for advanced therapies continues to rise, the ability to manufacture these products efficiently will be paramount. ChemT's advancements in AI-driven biomanufacturing could play a critical role in facilitating faster and more reliable access to life-saving treatments for patients worldwide.